Impact of Body Mass Index in Patients with Tricuspid Regurgitation After Transcatheter Edge-to-edge Repair

Overview

Journal Clin Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2023 Oct 4

PMID 37792020

Authors

Johanna Vogelhuber

Tetsu Tenaka

Mitsumasa Sudo

Atsushi Sugiura

Can Ozturk

Refik Kavsur

Anika Donner

Georg Nickenig

Sebastian Zimmer

Marcel Weber

Nihal Wilde

Affiliations

Soon will be listed here.

Abstract

Background: Obesity and underweight represent classical risk factors for outcome in patients treated for cardiovascular disease. This study describes the impact of different body mass index (BMI) categories on 1-year clinical outcome in patients with tricuspid regurgitation (TR) undergoing transcatheter-edge-to-edge repair (TEER).

Methods: We analyzed 211 consecutive patients (age 78.3 ± 7.2 years, 55.5% female, median EuroSCORE II 9.6 ± 6.7) with tricuspid regurgitation undergoing TEER from June 2015 until May 2021. Patients were prospectively enrolled in our single center registry and were retrospectively analyzed. Patients were stratified according to body mass index (BMI) into 4 groups: BMI < 20 kg/m (underweight), BMI 20.0 to < 25.0 kg/m (normal weight), BMI 25.0 to > 30.0 kg/m (overweight) and BMI ≥ 30 kg/m (obese).

Results: Kaplan-Meier survival curves demonstrated inferior survival for underweight and obese patients, but comparable outcomes for normal and overweight patients (global log rank test, p < 0.01). Cardiovascular death was significantly higher in underweight patients compared to the other groups (24.1% vs. 7.0% vs. 6.3% vs. 6.4%; p < 0.01). Over all, there were comparable rates of bleeding, stroke and myocardial infarction. Multivariable Cox regression analysis (adjusted for age, gender, coronary artery disease, chronic obstructive pulmonary disease, tricuspid annular plane systolic excursion, left-ventricular ejection fraction) confirmed underweight (HR 3.88; 95% CI 1.64-7.66; p < 0.01) and obesity (HR 3.24; 95% CI 1.37-9.16; p < 0.01) as independent risk factors for 1-year all-cause mortality.

Conclusions: Compared to normal weight and overweight patients, obesity and underweight patients undergoing TEER display significant higher 1-year all-cause mortality.

Citing Articles

Protruding and Ulcerated Aortic Atheromas as Predictors of Periprocedural Ischemic Stroke Post-Transcatheter Aortic Valve Replacement.

Kikuchi S, Trimaille A, Carmona A, Truong D, Matsushita K, Marchandot B JACC Asia. 2025; 5(2):258-269.

PMID: 39967216 PMC: 11840235. DOI: 10.1016/j.jacasi.2024.10.020.

Prognostic impact of being underweight in patients undergoing mitral TEER: The OCEAN-Mitral registry.

Higuchi R, Izumo M, Izumi Y, Saji M, Isobe M, Akashi Y ESC Heart Fail. 2024; 12(1):408-417.

PMID: 39308333 PMC: 11769672. DOI: 10.1002/ehf2.15047.

References

Allison D, Fontaine K, Manson J, Stevens J, VANITALLIE T . Annual deaths attributable to obesity in the United States. JAMA. 1999; 282(16):1530-8. DOI: 10.1001/jama.282.16.1530. View

Hahn R, Zamorano J . The need for a new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging. 2017; 18(12):1342-1343. DOI: 10.1093/ehjci/jex139. View

Kalbacher D, Tigges E, Boekstegers P, Puls M, Plicht B, Eggebrecht H . Underweight is associated with inferior short and long-term outcomes after MitraClip implantation: Results from the German TRAnscatheter mitral valve interventions (TRAMI) registry. Am Heart J. 2020; 222:73-82. DOI: 10.1016/j.ahj.2019.12.022. View

BRAUNWALD N, ROSS Jr J, Morrow A . Conservative management of tricuspid regurgitation in patients undergoing mitral valve replacement. Circulation. 1967; 35(4 Suppl):I63-9. DOI: 10.1161/01.cir.35.4s1.i-63. View

Genereux P, Piazza N, Alu M, Nazif T, Hahn R, Pibarot P . Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol. 2021; 77(21):2717-2746. DOI: 10.1016/j.jacc.2021.02.038. View

Romero-Corral A, Montori V, Somers V, Korinek J, Thomas R, Allison T . Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006; 368(9536):666-78. DOI: 10.1016/S0140-6736(06)69251-9. View

van der Boon R, Chieffo A, Dumonteil N, Tchetche D, Van Mieghem N, Buchanan G . Effect of body mass index on short- and long-term outcomes after transcatheter aortic valve implantation. Am J Cardiol. 2012; 111(2):231-6. DOI: 10.1016/j.amjcard.2012.09.022. View

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J . 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2021; 60(4):727-800. DOI: 10.1093/ejcts/ezab389. View

Konigstein M, Havakuk O, Arbel Y, Finkelstein A, Ben-Assa E, Leshem Rubinow E . The obesity paradox in patients undergoing transcatheter aortic valve implantation. Clin Cardiol. 2015; 38(2):76-81. PMC: 6711073. DOI: 10.1002/clc.22355. View

10.

Kappetein A, Head S, Genereux P, Piazza N, Van Mieghem N, Blackstone E . Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2012; 145(1):6-23. DOI: 10.1016/j.jtcvs.2012.09.002. View

11.

Chrysant S, Chrysant G . New insights into the true nature of the obesity paradox and the lower cardiovascular risk. J Am Soc Hypertens. 2013; 7(1):85-94. DOI: 10.1016/j.jash.2012.11.008. View

12.

Omran H, Pfister R, Ehrenfels M, Korber M, Baldus S, Friedrichs K . Prognostic Performance of the Surgical TRI-SCORE Risk Score in Patients Undergoing Transcatheter Tricuspid Valve Treatment. JACC Cardiovasc Interv. 2022; 15(19):1996-1998. DOI: 10.1016/j.jcin.2022.05.031. View

13.

Mehta L, Devlin W, McCullough P, ONeill W, Skelding K, Stone G . Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol. 2007; 99(7):906-10. DOI: 10.1016/j.amjcard.2006.11.038. View

14.

Mangieri A, Pagnesi M, Regazzoli D, Laricchia A, Ho E, Goldberg Y . Future Perspectives in Percutaneous Treatment of Tricuspid Regurgitation. Front Cardiovasc Med. 2020; 7:581211. PMC: 7591745. DOI: 10.3389/fcvm.2020.581211. View

15.

Batty G, Shipley M, Jarrett R, Breeze E, Marmot M, Davey Smith G . Obesity and overweight in relation to disease-specific mortality in men with and without existing coronary heart disease in London: the original Whitehall study. Heart. 2005; 92(7):886-92. PMC: 1860716. DOI: 10.1136/hrt.2005.072637. View

16.

Ruf T, Hahn R, Kreidel F, Beiras-Fernandez A, Hell M, Gerdes P . Short-Term Clinical Outcomes of Transcatheter Tricuspid Valve Repair With the Third-Generation MitraClip XTR System. JACC Cardiovasc Interv. 2021; 14(11):1231-1240. DOI: 10.1016/j.jcin.2021.03.033. View

17.

Schueler R, Ozturk C, Sinning J, Werner N, Welz A, Hammerstingl C . Impact of baseline tricuspid regurgitation on long-term clinical outcomes and survival after interventional edge-to-edge repair for mitral regurgitation. Clin Res Cardiol. 2016; 106(5):350-358. DOI: 10.1007/s00392-016-1062-1. View

18.

Yzeiraj E, Bijuklic K, Tiburtius C, Witt J, Krause K, Steude J . Tricuspid regurgitation is a predictor of mortality after percutaneous mitral valve edge-to-edge repair. EuroIntervention. 2017; 12(15):e1817-e1824. DOI: 10.4244/EIJ-D-16-00909. View

19.

Benfari G, Antoine C, Miller W, Thapa P, Topilsky Y, Rossi A . Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction. Circulation. 2019; 140(3):196-206. DOI: 10.1161/CIRCULATIONAHA.118.038946. View

20.

Hahn R . Tricuspid regurgitation: finally unforgettable!. Eur Heart J Cardiovasc Imaging. 2019; 21(2):166-167. DOI: 10.1093/ehjci/jez249. View